We canโt show the full text here under this license. Use the link below to read it at the source.
Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database
How weight-loss medicines relate to digestive side effects: a real-world study using FDA reports
AI simplified
Abstract
Among 34,396 adverse events related to obesity treatment, 8,844 digestive system adverse events were analyzed.
- Tirzepatide showed fewer reported digestive system adverse events compared to semaglutide and liraglutide.
- Semaglutide and liraglutide were strongly correlated with reports of non-lethal pancreatitis.
- Bupropion-naltrexone had the highest percentage of digestive system adverse events, at 31.65%, with a significant signal for mouth and lips adverse events.
- Orlistat demonstrated the highest association with gastrointestinal adverse events, as indicated by a reporting odds ratio of 3.30.
- Phentermine-topiramate was linked to hepatobiliary adverse events, with a reporting odds ratio of 6.13, warranting further investigation.
AI simplified
Key numbers
31.65%
Digestive Adverse Events Reporting Rate
Percentage of total adverse events associated with bupropion-naltrexone.
3.30
Orlistat Gastrointestinal Ratio
Reporting for gastrointestinal adverse events associated with orlistat.
Lowest
Tirzepatide Digestive Adverse Events Incidence
Comparison of incidence rates of dsAEs across different AOMs.